S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

$1.81
-0.05 (-2.69%)
(As of 03/28/2024 ET)
Today's Range
$1.80
$1.88
50-Day Range
$1.40
$2.78
52-Week Range
$0.66
$10.47
Volume
70,165 shs
Average Volume
64,832 shs
Market Capitalization
$29.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Alaunos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
10.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.62mentions of Alaunos Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($1.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.54 out of 5 stars

Medical Sector

890th out of 939 stocks

Pharmaceutical Preparations Industry

419th out of 444 stocks

TCRT stock logo

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

TCRT Stock Price History

TCRT Stock News Headlines

Werewolf Therapeutics Inc (HOWL)
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Recap: Alaunos Therapeutics Q3 Earnings
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics Inc TCRT
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
8-K: Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc.
See More Headlines
Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRT
Employees
34
Year Founded
N/A

Profitability

Net Income
$-37,730,000.00
Pretax Margin
-243,039.98%

Debt

Sales & Book Value

Annual Sales
$2.92 million
Book Value
$2.67 per share

Miscellaneous

Free Float
15,058,000
Market Cap
$29.05 million
Optionable
Optionable
Beta
-0.31
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

TCRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Alaunos Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares.
View TCRT analyst ratings
or view top-rated stocks.

How have TCRT shares performed in 2024?

Alaunos Therapeutics' stock was trading at $1.0605 at the start of the year. Since then, TCRT shares have increased by 70.7% and is now trading at $1.81.
View the best growth stocks for 2024 here
.

When is Alaunos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our TCRT earnings forecast
.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its earnings results on Tuesday, November, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics shares reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Alaunos Therapeutics' major shareholders?

Alaunos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include MSD Partners L.P. (94.40%), Commerce Bank (2.72%), Magnolia Capital Advisors LLC (0.17%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma.
View institutional ownership trends
.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners